Skip to main content
PCSA
NASDAQ Life Sciences

Processa 10-Q: $180.2M Cash but Going Concern Doubt Tied to Series A Conversion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.86
Mkt Cap
$5.205M
52W Low
$1.041
52W High
$8.88
52W Position info
79% above low
Off High info
79% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

PCSA sits 79% above its 52-week low of $1.041 on light trading volume (0.2× avg).

Summary

Processa ended Q3 2026 with $180.2M in cash after the Vidya deal and $200M PIPE, but the 10-Q keeps a going-concern warning because the Series A conversion depends on a stockholder vote expected in Q1 2027 — and failure would let holders demand cash.


Key Events · Earnings and Guidance · PCSA

  • Going Concern Doubt Persists

    Despite $180.2M of cash at September 30, 2026, management concluded substantial doubt about continuing as a going concern exists because the Series A preferred conversion requires stockholder approval and, if not obtained within nine months of issuance, holders can require cash settlement of the undelivered shares.

  • Q3 Loss Driven by IPR&D Write-Off

    Net loss was $183.2M for the quarter and $189.8M for the nine months, including a non-cash $178.0M acquired IPR&D expense from the Vidya asset acquisition; operating cash use was only $10.8M for the nine months.

  • Series A Conversion Vote in Q1 2027

    The 306,574,202 as-converted Series A shares (plus 1,047,524 assumed options) need stockholder approval; management expects the meeting in the first quarter of 2027, and failure triggers the cash-settlement right.

  • Generian FcRn Option Signed

    On October 12, 2026 the Vidya subsidiary paid a $4.0M non-refundable upfront plus $0.5M R&D reimbursement for an exclusive option to license Generian's oral FcRn inhibitor program, expected to be expensed in Q4 2026.


Analysis · PCSA · Life Sciences

Processa closed the Vidya acquisition and $200M PIPE in July, leaving it with $180.2M of cash at September 30, 2026 — enough to fund operations into the second half of 2029. Yet the 10-Q states that substantial doubt about the company's ability to continue as a going concern persists: the Series A preferred stock only converts if stockholders approve the share issuance, and if that approval is not obtained within nine months of issuance, holders can demand cash for the undelivered shares. Management plans to hold the vote in the first quarter of 2027. The quarter's $183.2M net loss is almost entirely the non-cash $178.0M write-off of acquired IPR&D from Vidya, not operating burn — operating cash use was $10.8M for the nine months. The filing also discloses a new October 12, 2026 Generian FcRn option deal with a $4.0M upfront payment that will hit Q4 R&D expense.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.04 to $8.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.86 info
Change: +$0.010 (+0.54%) info
Market Cap: $5.205M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.86 info
Change: -$0.090 (-5%) info
Market Cap: $5.205M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.86 info
Change: -$0.030 (-2%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info